Drugs / Ingenol disoxate
Ingenol disoxate
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02600598 | Jul → Dec 2016 | actinic keratosis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02650505 | Feb → Jun 2016 | actinic keratosis | LEO Pharma | Completed | No outcome recorded |
| Phase 1 | NCT02424305 | May → Jul 2015 | actinic keratosis | LEO Pharma | Completed | No outcome recorded |
| Phase 1/23 trials · 3 met primary | ||||||
| Phase 1/2 | NCT02100813 | May 2014 → Mar 2015 | actinic keratosis | LEO Pharma | Completed | Met primary |
| Phase 1/2 | NCT02120456 | May 2014 → May 2015 | actinic keratosis | LEO Pharma | Completed | Met primary |
| Phase 1/2 | NCT01922050 | Oct 2013 → Nov 2014 | actinic keratosis | LEO Pharma | Completed | Met primary |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT02575950 | Jun 2016 → Apr 2017 | acne | LEO Pharma | Completed | Met primary |
| Phase 2 | NCT02305888 | Mar → Jul 2015 | actinic keratosis | LEO Pharma | Completed | No outcome recorded |
| Phase 35 trials · 4 met primary · 1 missed | ||||||
| Phase 3 | NCT03115476 | Jun 2017 → Mar 2018 | actinic keratosis, squamous cell carcinoma | LEO Pharma | Terminated | Missed primary |
| Phase 3 | NCT02549339 | Nov 2015 → Aug 2016 | actinic keratosis | LEO Pharma | Completed | Met primary |
| Phase 3 | NCT02547233 | Nov 2015 → Nov 2016 | actinic keratosis | LEO Pharma | Completed | Met primary |
| Phase 3 | NCT02549352 | Nov 2015 → Sep 2016 | actinic keratosis | LEO Pharma | Completed | Met primary |
| Phase 3 | NCT02547363 | Nov 2015 → Aug 2016 | actinic keratosis | LEO Pharma | Completed | Met primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ingenol Disoxate | “A dose-finding trial with a novel ingenol derivative (ingenol disoxate: LEO 43204) for field treatment of actinic keratosis on full face or 250 cm(2) on the chest.” PMID 28264612 ↗ Apr 20173“Ingenol disoxate (LEO 43204) is a field therapy in development for the treatment of actinic keratosis (AK) on areas between 25 and 250 cm2.” PMID 29204958 ↗ Mar 2018 “Three-day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: A Phase II Trial.” PMID 29399263 ↗ Dec 2017 |
| Known as | Disoxate d'ingenol | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989918 ↗ |
| Known as | Disoxato de ingenol | ChEMBL registry synonym — accepted as the source's own label CHEMBL3989918 ↗ |
| Known as | LEO 43204 | “A dose-finding trial with a novel ingenol derivative (ingenol disoxate: LEO 43204) for field treatment of actinic keratosis on full face or 250 cm(2) on the chest.” PMID 28264612 ↗ Apr 201711“Ingenol disoxate (LEO 43204) is a field therapy in development for the treatment of actinic keratosis (AK) on areas between 25 and 250 cm2.” PMID 29204958 ↗ Mar 2018 “Three-day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: A Phase II Trial.” PMID 29399263 ↗ Dec 2017 |
| Known as | LEO 43204 Gel | “LEO 43204 Gel, 0.037%” NCT02600598 ↗ |
| Modality | Small molecule | — CHEMBL3989918 ↗ |
| Route | Topical | “Ingenol disoxate gel is a topical field therapy for AK.” PMID 28264612 ↗ Apr 2017 |